Renal Denervation for Treating Resistant Hypertension: Current Evidence and Future Insights from a Global Perspective
Table 2
Comparison between Symplicity HTN-1 and HTN-2 trials.
Trial
Patients characteristics
Study design
Mean values of baseline BP
Main results
Side effects
Symplicity HTN-1
45 patients, mean age 58 ± 9 years
Proof-of-principle, nonrandomized
177/101 ± 20/15 mmHg
At 6 months showed a mean decrease in systolic and diastolic BP of 25 mmHg and 11 mmHg respectively. Reduction in renal norepinephrine production by 47% in 10 patients
The side effects were one case of renal artery dissection and another with a prior renal artery stenosis.
Symplicity HTN-2
106 (52 RD, 54 controls). Mean age 58 ± 12 years in both groups
RD group had mean office BP reduction of 20/7 and 32/12 mmHg by 1 and 6 months following RD. Nineteen patients had a reduction in systolic BP to less than 140 mmHg in this same group
One case of postprocedural hypotension. A patient with single femoral artery pseudoaneurysm and 7 patients developed intraprocedural bradycardia
